[ScinoPharm] May 2026 Revenue of NT$175 Million (YoY -33.2%)
ScinoPharm Taiwan (TWSE: 1789), operating in the biotech and medical industry, announced its monthly revenue for May 2026 reached NT$175,224 thousand (approx. NT$175 million), representing a 33.2% decrease compared to the same month last year.
📋 Article Processing Timeline
- 📰 Published: May 1, 2026 at 09:00
- 🔍 Collected: June 12, 2026 at 08:00 (1007h 0m after Published)
- 🤖 AI Analyzed: June 12, 2026 at 16:41 (8h 41m after Collected)
Company Code: 1789
Company Name: ScinoPharm
Industry: Biotechnology and Medical
Date: 2026-05
Monthly Revenue: NT$ 175,224 thousand (NT$ 175 million)
Year-on-Year Change: -33.2%
Company Name: ScinoPharm
Industry: Biotechnology and Medical
Date: 2026-05
Monthly Revenue: NT$ 175,224 thousand (NT$ 175 million)
Year-on-Year Change: -33.2%
FAQ
What was ScinoPharm's revenue for May 2026?
The monthly revenue was NT$175,224 thousand (approximately NT$175 million), representing a 33.2% year-on-year decrease.
What is ScinoPharm's core business?
The company specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and provides CDMO services.
What is ScinoPharm's stock listing code?
Its listing code on the Taiwan Stock Exchange (TWSE) is 1789.